Illumina Unveils Billion Cell Atlas to Power AI-Driven Drug Discovery

Reuters01-13
<a href="https://laohu8.com/S/ILMN">Illumina</a> Unveils Billion Cell Atlas to Power AI-Driven Drug Discovery

Illumina Inc. has announced the development of the Illumina Billion Cell Atlas, a comprehensive data product designed to power the next generation of drug discovery and artificial intelligence in the pharmaceutical industry. The Billion Cell Atlas, part of Illumina’s BioInsight business, offers expansive multi-billion cell datasets and advanced disease-specific perturbation data, supporting next-generation cellular modeling and research. This initiative is a step toward an ultimate goal of creating a 5 billion single-cell resource. Illumina CEO Jacob Thaysen is scheduled to present more details about this and other multiomics initiatives at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA61945) on January 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment